

[Sulfasalazine](#)

Essential medicine status

Section:

[17. Gastrointestinal medicines](#) [17.3. Anti-inflammatory medicines](#)

ATC codes: [A07EC01](#)

Indication

Crohn disease site ICD11 code: [DD70.Z](#)

INN

Sulfasalazine

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid: 500 mg

Local > Rectal > Suppository: 500 mg

Local > Rectal > Retention enema: 3 g per 100 mL

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1987 ([TRS 770](#))

Changed in 1993 ([TRS 850](#))

Changed in 1997 ([TRS 882](#))

Changed in 2003 ([TRS 920](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[mesalazine](#) (ATC codes: [A07EC02](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Sulfasalazine](#)

DrugBank

[Sulfasalazine](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended mesalazine be specified as a therapeutic alternative under the square box listing for sulfasalazine on the EML for this indication.